Improving the effectiveness of docetaxel for prostate cancer treatment
Enhancing the Efficacy of Docetaxel in Prostate Cancer
This study is looking at ways to make the chemotherapy drug docetaxel work better for men with advanced prostate cancer by figuring out why some people don’t respond well to it, and it hopes to find new treatment options that are tailored to each patient’s unique genetics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10893328 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of docetaxel, a chemotherapy drug, for men with advanced prostate cancer. It focuses on understanding why some patients do not respond well to this treatment and aims to identify molecular markers that could predict resistance. By studying mouse models and patient samples, the research seeks to uncover the biological mechanisms behind treatment failure and explore new drug combinations that could improve outcomes. Patients may benefit from personalized treatment strategies based on their unique genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant or castration-sensitive prostate cancer who are undergoing treatment with docetaxel.
Not a fit: Patients with early-stage prostate cancer or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for men with metastatic prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown that understanding molecular mechanisms of drug resistance can lead to significant advancements in cancer treatment, suggesting this approach has potential for success.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Balk, Steven P. — Beth Israel Deaconess Medical Center
- Study coordinator: Balk, Steven P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.